Cholesterol biosynthesis inhibitor RO 48‑8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway.
Animals
Benzophenones
/ pharmacology
Carcinoma, Pancreatic Ductal
/ drug therapy
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cholesterol
/ biosynthesis
Cyclin B1
/ metabolism
Cyclin E
/ metabolism
Humans
Lipid Metabolism
/ drug effects
MAP Kinase Signaling System
/ drug effects
Male
Mice
Mice, Nude
Pancreatic Neoplasms
/ drug therapy
Phosphorylation
Proliferating Cell Nuclear Antigen
/ metabolism
Xenograft Model Antitumor Assays
RO 48‑8071
pancreatic ductal adenocarcinoma
proliferation
viability
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
13
02
2021
accepted:
12
07
2021
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
27
1
2022
Statut:
ppublish
Résumé
The morbidity and mortality of pancreatic cancer have been continuously increasing, causing seven deaths per 100,000 individuals/year. At present, effective therapies are severely lacking, thus, highlighting the importance of developing novel therapeutic approaches. The present study aimed to investigate the inhibitory roles of the 2,3‑oxidosqualene cyclase inhibitor, RO 48‑8071 (RO), on pancreatic ductal adenocarcinoma. RO was used to treat the pancreatic cancer cell line (PANC‑1)
Identifiants
pubmed: 34590153
doi: 10.3892/mmr.2021.12468
pii: 828
pmc: PMC8503744
doi:
pii:
Substances chimiques
Benzophenones
0
Cyclin B1
0
Cyclin E
0
Proliferating Cell Nuclear Antigen
0
p27 antigen
0
Ro 48-8071
161582-11-2
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Eur J Pharmacol. 2015 Oct 15;765:415-28
pubmed: 26358205
Cell Mol Life Sci. 2006 Feb;63(3):255-67
pubmed: 16378247
Nat Rev Mol Cell Biol. 2008 Feb;9(2):125-38
pubmed: 18216769
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Nat Rev Cancer. 2016 Sep;16(9):553-65
pubmed: 27444064
PLoS One. 2013 May 17;8(5):e62823
pubmed: 23690956
Breast Cancer Res Treat. 2014 Jul;146(1):51-62
pubmed: 24878988
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2473-8
pubmed: 25675507
J Recept Signal Transduct Res. 2015;35(6):600-4
pubmed: 26096166
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):45-55
pubmed: 28404111
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Trends Cancer. 2018 Jun;4(6):418-428
pubmed: 29860986
J Mol Graph Model. 2011 Apr;29(6):795-9
pubmed: 21315634
Cancer Lett. 2013 Feb 1;329(1):9-16
pubmed: 22960596
Drugs. 2007;67(1):11-6
pubmed: 17209661
Biochim Biophys Acta. 2014 Sep;1843(9):1839-50
pubmed: 24769209
Cell Cycle. 2005 Nov;4(11):1491-4
pubmed: 16258277
Onco Targets Ther. 2016 May 30;9:3223-32
pubmed: 27313468
Sci Rep. 2015 Mar 12;5:9054
pubmed: 25761781
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
N Engl J Med. 2011 Aug 25;365(8):768-9; author reply 769
pubmed: 21864184
Science. 2002 Dec 6;298(5600):1911-2
pubmed: 12471242
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Endocr Relat Cancer. 2018 Oct;25(10):821-836
pubmed: 29848667
Pharmacol Ther. 2014 Jul;143(1):87-110
pubmed: 24582968
Food Funct. 2016 Oct 12;7(10):4299-4309
pubmed: 27722367
Oncotarget. 2017 Jul 18;8(29):47250-47268
pubmed: 28467790
Sci Rep. 2015 Feb 04;5:8243
pubmed: 25649888
J Cell Biochem. 2019 Mar;120(3):4268-4277
pubmed: 30302806
J Cell Biochem. 2019 Apr;120(4):5033-5041
pubmed: 30506710
Anticancer Agents Med Chem. 2012 May;12(4):303-15
pubmed: 22413970
Gastroenterology. 1992 Sep;103(3):982-9
pubmed: 1499946
J Lipid Res. 1997 Feb;38(2):373-90
pubmed: 9162756